The Neurodegenerative Diseases Research Unit (NDRU) focuses on atypical parkinsonism syndromes to unravel molecular genetic mechanisms involved in the pathophysiology and to discover targets for rational therapeutic development. Over the last year we have undertaken several ambitious projects. In collaboration with the Johns Hopkins Pathology department, we performed exome sequencing of a pathologically confirmed cohort of dementia with Lewy bodies (DLB) patients. Our study found that 25% of cases carried either a high risk variant or causative mutation in one of three genes (GBA, PSEN1, APP). Further we confirmed that the APOE e4 allele significantly increases risk for disease and decreases survival. Taken together, these results highlight that genetic factors are playing a prominent role in the pathobiology of DLB, and strongly support the notion that DLB occurs along a spectrum between Parkinson disease and Alzheimer dementia. As part of a multi-center, international collaboration we performed a genome-wide association study in multiple system atrophy (MSA). This study found several interesting genetic loci that could reveal important insights into the disease etiology. Follow up replication studies of larger cohorts will have to be performed to confirm their role in MSA. Ongoing projects in our laboratory include: (1) genotype-phenotype analyses of pathologically confirmed atypical parkinsonism cohorts using custom-designed genotyping chips; (2) a genome-wide association study in DLB; (3) candidate gene analyses in MSA and DLB; and (4) a natural history study of atypical parkinsonism syndromes. In summary, we have successfully applied modern genomic approaches. The projects highlighted above have already identified several genetic variants that are implicated in the pathobiology of DLB and MSA. Additional follow-up studies are required for replication, fine-mapping and a more refined dissection of genetic factors involved in atypical parkinsonism syndromes.
| Nicolas, Aude (see original citation for additional authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97:1268-1283.e6 |
| Guerreiro, Rita; Ross, Owen A; Kun-Rodrigues, Celia et al. (2018) Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol 17:64-74 |
| Blauwendraat, Cornelis; Reed, Xylena; Kia, Demis A et al. (2018) Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurol : |
| Blauwendraat, Cornelis; Kia, Demis A; Pihlstrøm, Lasse et al. (2018) Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. Neurobiol Aging 64:159.e5-159.e8 |
| Chen, Xi; Scholz, Sonja W (2018) Identification of new ?-synuclein regulator by nontraditional drug development pipeline. Mov Disord 33:402 |
| Scholz, Sonja W; Houlden, Henry (2017) Author response: A genome-wide association study in multiple system atrophy. Neurology 88:1296-1297 |
| Geiger, Joshua T; Schindler, Alice B; Blauwendraat, Cornelis et al. (2017) TUBB2B Mutation in an Adult Patient with Myoclonus-Dystonia. Case Rep Neurol 9:216-221 |
| Blauwendraat, Cornelis; Faghri, Faraz; Pihlstrom, Lasse et al. (2017) NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging 57:247.e9-247.e13 |
| Scholz, Sonja W (2017) Restless legs syndrome: is it all in the genes? Lancet Neurol 16:859-860 |
| Blauwendraat, Cornelis; Nalls, Mike A; Federoff, Monica et al. (2017) ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies. Mov Disord 32:298-299 |
Showing the most recent 10 out of 15 publications
